Immunoglobulin G

EUROIMMUN Anti-SARS-CoV-2 S1 Curve ELISA Receives FDA Emergency Use Authorization

Retrieved on: 
Tuesday, October 5, 2021
Health, FDA, Medical Devices, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, ELISA, Food, PCR, Longevity, Serum, Vaccine, PKI, Solution, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Immunity, CLIA, Immunoglobulin G, CEO, Company, Antibody, EUA, Clinical Laboratory, Science, PerkinElmer, Severe acute respiratory syndrome coronavirus 2, Research, Infection, RBD, Laboratory, Quality of life, NYSE, Plasma

EUROIMMUN , a PerkinElmer, Inc. company (NYSE: PKI), announced today that the U.S. Food and Drug Administration has provided Emergency Use Authorization (EUA) for its Anti-SARS-CoV-2 S1 CurveTM ELISA (IgG) .

Key Points: 
  • EUROIMMUN , a PerkinElmer, Inc. company (NYSE: PKI), announced today that the U.S. Food and Drug Administration has provided Emergency Use Authorization (EUA) for its Anti-SARS-CoV-2 S1 CurveTM ELISA (IgG) .
  • This assay allows for the qualitative and semi-quantitative detection of IgG antibodies formed against the SARS-CoV-2 S1 antigen, in human serum and plasma.
  • For this reason, S1 based tests play a critical role in ongoing vaccine development programs and in research efforts to examine the immunity of individuals previously infected by SARS-CoV-2.
  • The assay can run manually or using the EUROLabTM Workstation ELISA , Sprinter XLTM and other third party ELISA platforms.

Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Tuesday, October 5, 2021
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Immunoglobulin G, Toxic shock syndrome, Immunosuppression, Pulmonary edema, Therapy, ATP, Cancer, Patient, Walter E. Washington Convention Center, Poster, Health, Immune system, D.C, Immunotherapy, Washington Convention Center, Intelligence, EST, List of life sciences, Walter, SITC, Society, Pharmaceutical industry, Vaccine

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through a potentially best-in-class, computationally evolved IL-2 human antibody, today announced the planned presentation of preclinical data on its lead investigational therapy, AU-007, at the Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting.

Key Points: 
  • Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through a potentially best-in-class, computationally evolved IL-2 human antibody, today announced the planned presentation of preclinical data on its lead investigational therapy, AU-007, at the Society for Immunotherapy of Cancers (SITC) 36th Annual Meeting.
  • The SITC meeting will run Nov. 10-14, 2021, in Washington D.C., as well as virtually.
  • We look forward to presenting preclinical data at the SITC Annual Meeting and to initiating clinical testing in patients with cancer by year end.
  • AU-007 is a computationally evolved, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2.

At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study

Retrieved on: 
Friday, October 1, 2021
Blood, Ulcerative colitis, Safety, LLY, University of Calgary, Friends, UC, Lilly, United European Gastroenterology, Colon, Extrapyramidal system, Private Securities Litigation Reform Act, Master jet base, Abdominal pain, C-reactive protein, Globe, Multimedia, U.S. Securities and Exchange Commission, Population, Immunoglobulin G, Crohn's disease, Eli Lilly and Company, Defecation, Biomarker, Form 10-K, Immune system, Form, Randomized controlled trial, University, Company, Family, Endoscopy, Disease, UEG, Inflammation, View, Association, Maintenance, NYSE, CRP, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Medical device

Both analyses will be presented virtually at United European Gastroenterology Week (UEG Week), taking place October 3-5, 2021.

Key Points: 
  • Both analyses will be presented virtually at United European Gastroenterology Week (UEG Week), taking place October 3-5, 2021.
  • Among patients treated with mirikizumab, results in symptomatic remission, rectal bleeding remission and stool frequency remission were comparable between biologic-nave patients and those who had prior experience with biologics.
  • Efficacy and Safety of Mirikizumab in Patients with Ulcerative Colitis: 104-Week Results from a Phase 2 Randomized Controlled Trial
    186 patients with moderately to severely active UC received treatment with mirikizumab.
  • At two years, 85.9% (67/78) of patients achieved rectal bleeding remission and 84.6% (66/78) of patients achieved stool frequency remission.

Merus Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Thursday, September 30, 2021
Immunoglobulin G, Patent, Therapy, Cancer, CSCS, Meru Networks, HER2, LGR5, Conference, Private Securities Litigation Reform Act, Patient, AACR, U.S. Securities and Exchange Commission, Zeno, ET, Growth, HER3, NRG1, COVID-19, Cell, EGFR, ADCC, Name, SEC, Metastasis, GLOBE, Vaccine

Zeno is an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced Biclonics that utilizes the Merus Dock & Block mechanism to inhibit the neuregulin/HER3 tumor-signaling pathway in solid tumors with NRG1 gene fusions (NRG1+).

Key Points: 
  • Zeno is an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced Biclonics that utilizes the Merus Dock & Block mechanism to inhibit the neuregulin/HER3 tumor-signaling pathway in solid tumors with NRG1 gene fusions (NRG1+).
  • In preclinical studies, Zeno also potently inhibits HER2/HER3 heterodimer formation and tumor growth in models harboring NRG1 fusions.
  • Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Curebase Solutions Supports Another InBios FDA Emergency Use Authorization for COVID-19 IgG Antibody Rapid Test

Retrieved on: 
Thursday, September 30, 2021
GMP, ISO, Federal Food, Drug, and Cosmetic Act, Infection, Clinical trial, PPA, Time, Diagnosis, FDA, Immunoglobulin G, Patient, Physician, Lviv, InBios, Virus, CEO, NPA, Antibody, EUA, SAN, USDA, Cros, COVID-19, Severe acute respiratory syndrome coronavirus 2, Research, Laboratory, Pharmaceutical industry, Medical device, Vaccine

This research resulted in FDA Emergency Use Authorization (EUA) for use in the United States.

Key Points: 
  • This research resulted in FDA Emergency Use Authorization (EUA) for use in the United States.
  • The InBios test includes all reagents and controls required to run 50 test specimens with results in approximately 20 minutes.
  • This rapid test is intended to identify individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
  • While the SCoV-2 Detect IgG Rapid Test has not been FDA cleared or approved, it has been authorized for emergency use by FDA under an EUA for use by authorized laboratories.

ILiAD Biotechnologies Reports Preliminary Data Demonstrating Pertussis Vaccine Candidate BPZE1, but Not Boostrix, Induces Functional Bactericidal Antibodies Against Pertactin Negative B. Pertussis

Retrieved on: 
Wednesday, September 29, 2021
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, People, Infection, Diphtheria, Review, Vaccine, SBA, Bordetella pertussis, Sneeze, PRN, Iliad, Private Securities Litigation Reform Act, Immunoglobulin G, Death, Link, Adult, Whooping cough, Environment, Twitter, Knowledge, LLC, Centers for Disease Control and Prevention, Disease, Infectious Diseases Society of America, Sinusitis, Â, Tetanus, Intelligence, Research, Forward-looking statement, Investment, AP, PHE, Industry, Vaccination, Public Health England, Pertussis, BPZE1, ILiAD Biotechnologies, LLC, Public Health England, PERTUSSIS, BPZE1, ILIAD BIOTECHNOLOGIES, LLC, PUBLIC HEALTH ENGLAND

Pertactin (PRN) is a highly immunogenic virulence factor secreted by Bordetella pertussis (B. pertussis).

Key Points: 
  • Pertactin (PRN) is a highly immunogenic virulence factor secreted by Bordetella pertussis (B. pertussis).
  • PHE performed testing on serum samples from BPZE1 and Boostrix vaccinated subjects, which were analyzed in a blinded fashion.
  • Furthermore, this preliminary set of samples from the Boostrix vaccinated group demonstrated no subjects with > 2x fold rise in SBA titres against PRN(-) B. pertussis (N = 0/17).
  • Its lead candidate, BPZE1, is the most advanced next generation vaccine for the prevention of pertussis (whooping cough), a serious disease caused by Bordetella pertussis.

Biliary Tract Cancer Pipeline Insight Landscape 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 28, 2021
Pharmaceutical, Health, Oncology, News, Clinical trial, II, Route of administration, Therapy, III, Administration, Merck & Co., Immunoglobulin G, PD-1, Route, Pembrolizumab, PD-L1, ADC, CDE, Biliary tract, Discovery, Medical imaging, Pharmaceutical industry

The "Biliary Tract Cancer - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biliary Tract Cancer - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This Biliary Tract Cancer - Pipeline Insight, 2021 provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Biliary Tract Cancer pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Biliary Tract Cancer R&D.
  • phase III include, Merck & Co.
    Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Biotech Support Group & Lawson Health Research Institute Enter Collaborative Research Agreement to Monitor Protease Inhibitor Function During Covid-19 Infections

Retrieved on: 
Tuesday, September 28, 2021
Blood, Peptide, ASMS, Goal, Business development, Partnership, Ingo Nugel, Robarts Research Institute, Research, Protein, Mass spectrometry, Patient, Protease, Risk, Partner, LC-MS, Lawson Health Research Institute, Infection, Inflammation, Health, Immunity, Society, Conference, Doctor of Philosophy, Cancer, COVID-19, Poster, Immunoglobulin G, Coagulation, MD, Western University, Biomarker, Business, Method, BSG, Medicine, Proteomics, Growth, Digestion, Disease, Type, Science, Founder, Severe acute respiratory syndrome coronavirus 2, Thrombosis, Lawson, Hospital, Degenerative disease, Enzyme, Intellectual property, Industry, American Society for Mass Spectrometry, Pharmaceutical industry, Vaccine

MONMOUTH JUNCTION, N.J. and LONDON, Ontario, Sept. 28, 2021 /PRNewswire-PRWeb/ -- Biotech Support Group and Lawson Health Research Institute announce a collaborative research agreement.

Key Points: 
  • MONMOUTH JUNCTION, N.J. and LONDON, Ontario, Sept. 28, 2021 /PRNewswire-PRWeb/ -- Biotech Support Group and Lawson Health Research Institute announce a collaborative research agreement.
  • The agreement supports further research to monitor protease inhibitor function acquired from blood collected from hospitalized patients with the SARS-CoV-2 (COVID-19) virus.
  • Lawson Health Research Institute is one of Canada's top hospital-based research institutes, tackling the most pressing challenges in health care.
  • As the research institute of London Health Sciences Centre and St. Joseph's Health Care London, our innovation happens where care is delivered.

New antibody detection platform offers accelerated multiplex detection of antibodies against pathogens or autoantibodies against biomarkers

Retrieved on: 
Tuesday, September 28, 2021
Serum, Immunoglobulin G, Immunoglobulin M, Autoantibody, RUO, Saliva, Antibody, Neurology, Immunoglobulin A, Serology, Technology, Research, Drug development, Cardiology, Plasma, Vaccine

The ability to preanalytically remove sample interferences from a larger sample and subsequently concentrate makes it possible to detect antibodies in low abundance from serum, plasma, saliva, or saline oral rinse samples.

Key Points: 
  • The ability to preanalytically remove sample interferences from a larger sample and subsequently concentrate makes it possible to detect antibodies in low abundance from serum, plasma, saliva, or saline oral rinse samples.
  • The patented VeraPrep process uses proprietary magnetic beads with unique, low nonspecific binding properties that isolate and remove interfering antibodies in the sample.
  • "The VeraPrep antibody detection technology offers a first of its kind platform that addresses unmet clinical needs," said John Forrest, Co-founder and Chief Executive Officer of Veravas.
  • Veravas is transforming laboratory medicine with a first of its kind, patented antibody detection platform to address unmet clinical needs.

Mustang Bio Announces MB-101 (IL13Rα2‐targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences

Retrieved on: 
Tuesday, September 28, 2021
Patent, Glioblastoma, Securities Act of 1933, Regulation, City of Hope, CD19, Private Securities Litigation Reform Act, NASDAQ, Translation, Conference, U.S. Securities and Exchange Commission, Hematological Cancer Research Investment and Education Act, Association, Immunoglobulin G, Lists of diseases, Ownership, Medulloblastoma, American Society of Clinical Oncology, CD137, Fortress Biotech, Phenotype, Mustang, CAR, Ependymoma, Research, Heritage, Forward-looking statement, Brain, Securities Exchange Act of 1934, City, SEC, Society, GLOBE, Pharmaceutical industry, Vaccine

Additional information about the brain cancer clinical trials can be found on clinicaltrials.gov using identifiers NCT04661384 , NCT02208362 and NCT04003649 .

Key Points: 
  • Additional information about the brain cancer clinical trials can be found on clinicaltrials.gov using identifiers NCT04661384 , NCT02208362 and NCT04003649 .
  • Mustang is developing MB101 as an optimized CAR T product incorporating enhancements in CAR design and T cell engineering to improve antitumor potency and T cell persistence.
  • Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for X-linked severe combined immunodeficiency.
  • Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (SEC).